

amendments are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments and additions.

Conclusion

Applicants believe that the subject matter of the pending claims is patentable and that the instant application should accordingly be allowed. If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney at (203) 812-6540.

Respectfully submitted,


Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Bayer Corporation
400 Morgan Lane
West Haven, CT 06516
(Tel) (203) 812-6450
(Fax) (203) 812-6459
e-mail: susan.pellegrino.b@bayer.com

Dated: January 7, 2002

Amended Claims (Attorney Docket No. LeA 34 992)

2/2/01

AM

1. (Amended) A method of preventing or treating Parkinson's disease comprising administering an effective amount of 2-[4-({[(2R)-8-isopropoxy-chroman-2-yl]methyl}amino)butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, its physiologically acceptable salts, hydrates or solvates.

2. (Amended) The method of claim 1 comprising administering an effective amount of 2-[4-({[(2R)-8-isopropoxy-chroman-2-yl]methyl}amino)butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide hydrochloride.

3. Cancelled.

4. Cancelled.

SEARCHED
INDEXED
MAILED
FILED
2/2/01

Amended Claims (Attorney Docket No. LeA 34 992)

Version with Markings to Show Changes to Claims

1. (Amended) A method of preventing or treating Parkinson's disease comprising administering an effective amount [Use] of 2-[4-({[(2R)-8-isopropoxy-chroman-2-yl]methyl}amino)butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, its physiologically acceptable salts, hydrates and/or solvates [for the production of a medicament for the prophylaxis and/or treatment of Parkinson's disease].
2. (Amended) The method of claim 1 comprising administering an effective amount of [Use according to Claim 1, the active compound being] 2-[4-({[(2R)-8-isopropoxy-chroman-2-yl]methyl}amino)butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide hydrochloride.
3. Cancelled.
4. Cancelled.